Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
Public ClinicalTrials.gov record NCT05645744. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Long-term Follow-up Study in Patients Previously Treated With Mustang Bio, Inc. CAR-T Cell Investigational Products
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A long-term follow-up study to assess safety and efficacy in patients previously treated with Mustang Bio chimeric antigen receptor (CAR)-T cell investigational products.
Study identification
- NCT ID
- NCT05645744
- Recruitment status
- Terminated
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 3 participants
Conditions and interventions
Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Chronic Lymphocytic Leukemia in Relapse
- Small Lymphocytic Lymphoma, Relapsed
- Waldenstrom's Macroglobulinemia Recurrent
- Follicular B-cell Non-Hodgkin's Lymphoma
- B-cell Lymphoma Refractory
- Mantle Cell Lymphoma Recurrent
- Hairy Cell Leukemia
- Diffuse Large B Cell Lymphoma
- Waldenstrom's Macroglobulinemia Refractory
- Mantle Cell Lymphoma Refractory
Interventions
- Prior MB-102 CAR-T cell investigational product. Biological
- Prior MB-106 CAR-T cell investigational product. Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 28, 2021
- Primary completion
- Apr 11, 2024
- Completion
- Apr 11, 2024
- Last update posted
- Jul 21, 2024
2021 – 2024
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC Irvine Health - Chao Family Comprehensive Cancer Center | Orange | California | 92868-3201 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| University of Rochester Medical Center | Rochester | New York | 14642 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05645744, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 21, 2024 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05645744 live on ClinicalTrials.gov.